Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .My regular readers know I believe the overall market is in extremely overbought territory. That said, the market indexes continue to trade at/near all-time highs and are showing resiliency despite a current government shutdown and a cle ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best biotech stocks with high potential. H.C. Wainwright analyst Joseph Pantginis reiterated a bullish stance on Viking Therapeutics, Inc. (NASDAQ:VKTX) on September 22, giving the stock a Buy rating with a $102 price target. Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results The analyst supported the rating with Viking Therapeutics, Inc.’s (NASDAQ:VKTX) promising market position, stating that the company’s competitive eff ...

In this article, I will explain—using back-of-the-envelope math and plain English—why the stock of Viking Therapeutics, Inc. (NASDAQ: VKTX ), one of the frontrunners in the GLP-1 weight-loss drug market, may represent a (relatively) de-risked investment opportunityI am a corporate lawyer with an MBA and a long-standing interest in value investing. After spending 7 years practicing at several prestigious Wall Street and Silicon Valley law firms as a corporate transactional lawyer, I founded and have been ope ...

In this article, I will explain—using back-of-the-envelope math and plain English—why the stock of Viking Therapeutics, Inc. (NASDAQ: VKTX ), one of the frontrunners in the GLP-1 weight-loss drug market, may represent a (relatively) de-risked investment opportunityI am a corporate lawyer with an MBA and a long-standing interest in value investing. After spending 7 years practicing at several prestigious Wall Street and Silicon Valley law firms as a corporate transactional lawyer, I founded and have been ope ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best strong buy stocks to invest in according to Wall Street. On September 22, BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics, Inc. (NASDAQ:VKTX) and set a $125.00 price target. Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results The analyst based the optimistic rating on the company’s strong position in the obesity and metabolic disease market, reasoning that the recent acquisitions conducted by t ...

Key Points Viking Therapeutics' shares plunged after mixed phase 2 results for a GLP-1 candidate. However, the data wasn't nearly as bad as the market's reaction suggested. Viking could soar on future progress with this and other candidates. 10 stocks we like better than Viking Therapeutics › Developing GLP-1 medicines is all the rage these days in the pharmaceutical and biotech industries. The market is growing rapidly, and many (if not most) leading drugmakers are looking to capitalize on the t ...

Group 1 - The article discusses the potential for undervalued stocks that are mispriced by the market as the end of Q3 approaches [1] - It suggests that investors may consider joining a platform for insights on these investment opportunities [1] Group 2 - There is a mention of a specific company, VKTX, indicating a potential interest in initiating a long position through stock or options purchases within the next 72 hours [2] - The article emphasizes that the opinions expressed are those of the author and not influenced by any compensation from companies mentioned [2]

Group 1 - The article discusses the potential for investing in undervalued stocks that are mispriced by the market as the third quarter comes to an end [1] - It suggests that investors may consider joining a platform called Out Fox The Street for insights on positioning in these stocks [1] Group 2 - There is a mention of a potential long position in VKTX, indicating that the analyst may initiate a beneficial investment in the stock or related derivatives within the next 72 hours [2] - The article emphasizes that the information provided is for informational purposes only and does not constitute a solicitation to buy or sell securities [3]

Group 1 - Viking Therapeutics (NASDAQ: VKTX) has gained attention in the drug obesity sector, indicating a growing interest in this market [1] - The analysis focuses on business models, earnings performance, and competitive positioning within the industry [1] - The author emphasizes the importance of fundamental analysis and long-term growth, particularly in sectors like AI, fintech, and technology [1] Group 2 - The article does not provide any specific financial data or performance metrics related to Viking Therapeutics or the broader drug obesity market [1]

Company Performance - Viking Therapeutics, Inc. closed at $25.09, reflecting a -5.78% change from the previous day, which is less than the S&P 500's daily loss of 0.5% [1] - Over the past month, shares of Viking Therapeutics gained 0.04%, outperforming the Medical sector's loss of 0.7% but lagging behind the S&P 500's gain of 2.74% [1] Financial Expectations - Analysts expect Viking Therapeutics to report earnings of -$0.71 per share, indicating a year-over-year decline of 222.73% [2] - For the full year, the Zacks Consensus Estimates project earnings of -$2.48 per share and revenue of $0 million, reflecting changes of -145.54% and 0% respectively from the previous year [2] Analyst Estimates - Recent changes to analyst estimates for Viking Therapeutics should be noted, as positive revisions are interpreted as a good sign for business outlook [3] - The Zacks Rank system, which integrates estimate changes, currently ranks Viking Therapeutics at 4 (Sell), with the consensus EPS estimate moving 2.44% lower over the past month [5] Industry Context - Viking Therapeutics operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 88, placing it in the top 36% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]